Teva Pharmaceutical Industries News

Tom Gayner of Markel Corp just reported his fourth quarter portfolio. During GuruFocus interview with Mr.

Gamida Cell announced today that the Gamida Cell-Teva Joint Venture , equally held by Gamida Cell and Teva Pharmaceutical Industries, has enrolled the last of 100 patients in the international, multi-center, pivotal registration, Phase III clinical trial of StemEx, a cell therapy product in development as an alternative therapeutic treatment for ... (more)

The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma JERUSALEM-- --Feb 13, 2012 - Gamida Cell announced today that the Gamida Cell-Teva Joint Venture , equally held by Gamida Cell and Teva Pharmaceutical Industries, has enrolled the last of 100 patients ... (more)

NASDAQ OMX Nordic The Disciplinary Committee of NASDAQ OMX Stockholm issues a warning to Active Biotech AB Stockholm, February 13, 2012 - The Disciplinary Committee of NASDAQ OMX Stockholm AB has found that the listed company Active Biotech AB has been in breach of the exchange's rules and regulations for issuers in respect of the information the ... (more)

Teva Pharmaceutical Industries Limited A A A' Product Pipeline Review A A A' H2 2011 - new company profile report published 2012-02-13 04:51:10 - Teva Pharmaceutical Industries Limited A A A' Product Pipeline Review A A A' H2 2011 - a new company profile report on companiesandmarkets.com Teva Pharmaceutical Industries Limited A A A' Product ... (more)

The company will unveil its latest earnings on Tuesday, Feb. 14. United Therapeutics is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular or infectious diseases and cancer.

U.S. regulators proposed guidelines for approving the first lower-cost copies of biologic drugs derived from living cells in a move that will help cut national health spending by an estimated $25 billion over a decade.

BioSante Pharmaceuticals, Inc. describes itself as a specialty pharmaceutical company focused on developing products for female sexual health and oncology.

Cubist Pharmaceuticals Inc said specialty medicines maker Hospira Inc filed a marketing application for a copycat version of Cubist's flagship antibiotic injection Cubicin.

BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of TEVA PHARMACEUTICAL-SP ADR , RADWARE LTD , Autonomy Corp PLC , USA MOBILITY INC , Cavco Industries Inc , NEXSTAR BROADCASTING GROUP-A and each have a high seasonal probability to go Up in the next weeks.

Watson Pharmaceuticals Inc. Chief Executive Officer Paul Bisaro is looking to acquire brand-name drug assets and make a future "'transformational'' purchase as he reshapes the generic-drug maker.

A reproductive rights group asked a federal judge to reopen a lawsuit over access to the emergency contraceptive Plan B, claiming the U.S. Food and Drug Administration has acted in "bad faith." The Center for Reproductive Rights , in a filing today in federal court in Brooklyn , New York , said reopening its 2005 case was the most efficient way for ... (more)

It is indicated in the treatment of the reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension.

Sales for Perrigo Co. probably grew at the slowest average pace in four years in the latest quarter because of a milder cold season this winter, Canaccord Genuity Corp., Harel Finance Ltd.

Sprint Nextel Corp. : FBR's channel checks indicate Sprint's solid execution continues and the firm reiterates an Outperform rating on the stock ahead of the company's Q4 results on February 8. FBR believes Sprint is on track to exceed consensus expectations in FY12.

Live audio webcasts can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com . Webcast replays will be archived for 90 days.

Teva Pharmaceutical was downgraded today by Morgan Stanley from overweight to equal-weight with a price target of $47, as the firm believes that the stock has gotten ahead of itself recent.

Analysts at BMO Capital Markets downgraded PNC Financial Services Group Inc from "outperform" to "market perform." PNC's shares closed at $62.20 on Friday.

Shares of PROLOR Biotech, Inc. have been on the move since we told readers about the company in January and jumped another 5.2% this past week.

Teva Pharmaceutical Industries Ltd was downgraded by research analysts at Morgan Stanley to an "equal weight" rating in a report issued on Monday.